Meteora Capital’s Drugs Made In America Acquisition Corp DMAA Stock Holding History

Meteora Capital’s Portfolio DMAA Stock Details DMAA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$3.99M	Buy	+380,299	New	+$3.97M	0.29%	97

Other funds holding DMAA

Karpus Investment Management Pittsford, New York $3.21B AUM 6.83% 1-Year Est. Return

First Trust Capital Management Chicago, Illinois $1.9B AUM 58.39% 1-Year Est. Return

Mizuho Securities USA New York $4.24B AUM 23.1% 1-Year Est. Return

Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return

Westchester Capital Management (New York) Valhalla, New York $2.21B AUM 26.02% 1-Year Est. Return

Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.27% 1-Year Est. Return

Wolverine Asset Management Chicago, Illinois $10.4B AUM 4.78% 1-Year Est. Return

Highbridge Capital Management New York $3.09B AUM 31.19% 1-Year Est. Return

Aristeia Capital Greenwich, Connecticut $4.82B AUM 24.94% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Meteora Capital's DMAA Position: Q1 2026 in Review

Meteora Capital opened a new position in Drugs Made In America Acquisition Corp (DMAA) in Q1 2026: 380,299 shares worth $3.99M. The stake represents 0.29% of the portfolio and ranks #97 among its holdings.

39 funds tracked by Wall St. Rank hold DMAA as of Q1 2026.

Meteora Capital held 380,299 shares of Drugs Made In America Acquisition Corp worth $3.99M as of Q1 2026.
Drugs Made In America Acquisition Corp was a new Meteora Capital position in Q1 2026.
Drugs Made In America Acquisition Corp made up 0.29% of Meteora Capital's portfolio in Q1 2026, its #97 holding.
39 funds tracked by Wall St. Rank held Drugs Made In America Acquisition Corp as of Q1 2026.

Based on Meteora Capital's 13F filing for Q1 2026, filed 15 May 2026.